New report calls for more equal access to type 1 diabetes technology

In our new report, Access For All: The impact of technology on the lives of people with type 1 diabetes we’ve updated the market research we first conducted in 2019 for Pathway to Choice, to see how things have progressed. The good news is that more people are using diabetes tech, but there’s still a long way to go. There are big differences in access across the UK, and many people are still missing out on devices that could make a huge difference in their daily lives.

The market research, conducted in autumn 2023, explored how people with type 1 and their families use these technologies and their impact. By understanding how people feel about these technologies, we can improve care and support for everyone with T1D.

The use of tech in 2024

Technology for managing type 1 diabetes has come a long way in recent years, with devices becoming more wearable, user-friendly, and integrated with mobile phones. These advancements ease the daily challenges of managing T1D, from insulin injections to monitoring glucose levels, and help reduce the risk of complications. Pioneering technology, like hybrid closed-loop systems, now reduces the number of daily decisions people with T1D have to make, helping to improve quality of life.

While great progress is being made—especially with hybrid closed-loop technology now available on the NHS in England, Scotland, and Wales, and under consideration in Northern Ireland—there are still major challenges. Limited availability of devices on the NHS and healthcare professionals not always recommending these technologies are significant barriers that need to be addressed.

Our Chief Executive, Karen Addington, said:

“Technology can truly transform the lives of people with type 1 diabetes. Devices that help with precise insulin dosing and continuous glucose monitors can reduce the daily stresses of managing T1D. But we know not everyone has equal access to these life-changing tools, and that needs to change. Exciting breakthroughs in cellular therapies offer hope for future treatments that could even cure type 1 diabetes. But right now, we need to make sure that everyone has access to the best technology available. That’s why we’ve done this market research—so we can better understand people’s experiences with diabetes tech and work to improve access for everyone.”

Key findings

Most people know about insulin injections, pumps, and glucose monitors like CGM and flash monitors, but only 25% have heard of HCL. Many try T1D tech because healthcare professionals recommend it, or they’re encouraged by friends and family who’ve used it. Barriers include limited access on the NHS, complicated devices, and devices’ appearance. Those using the tech say it helps with blood glucose management and makes them feel happier and less anxious, especially with HCL. There’s also a lot of interest in future treatments like beta cell transplants, but many are hesitant to be among the first to try new treatments.

Recommendations

The report recommends increasing awareness of hybrid closed-loop (HCL) systems, ensuring those who could benefit are included in the rollout, and providing comprehensive training for healthcare professionals. It also calls for a national diabetes registry, an early detection programme for type 1 diabetes, and ongoing support for those testing positive for biological markers. Additionally, the report urges the approval of drugs delaying type 1 diabetes by NICE, better patient education on emerging therapies, and increased awareness of clinical trials for future treatments.

Moving forward together

We’re committed to ensuring that no one living with T1D is left behind. Using the findings of the report, we’re working with the NHS, Parliamentarians, other charities and industry stakeholders to address systemic issues across the UK to ensure fair and equitable access to existing and emerging treatments to everyone with T1D.

Read the full report Access For All: The impact of technology on the lives of people with type 1 diabetes

The survey report was conceived, developed and led by Breakthrough T1D under its Access for All programme which is sponsored by Abbott, Dexcom and Insulet.

Sanofi provided funding to Breakthrough T1D to support costs associated with this research and report but had no influence or editorial involvement in the project or its outputs.